Zeposia vs. Mayzent

Zeposia (ozanimod) and Mayzent (siponimod) are sphingosine 1- phosphate receptor modulators used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults.

Side effects of Zeposia and Mayzent that are similar include liver transaminase elevation and high blood pressure (hypertension).

Side effects of Zeposia that are different from Mayzent include upper respiratory infection, dizziness on standing (orthostatic hypotension), urinary tract infection (UTI), back pain, and upper abdominal pain.

Side effects of Mayzent that are different from Zeposia include headache, falls, swelling of extremities, nausea, dizziness, diarrhea, slow heart rate, and pain in extremities.

Both Zeposia and Mayzent may interact with anti-neoplastic medications, immune-modulating drugs, immunosuppressive therapies, anti-arrhythmics, and live attenuated vaccines.

Zeposia may also interact with strong CYP2C8 inhibitors (e.g., gemfibrozil), BCRP inhibitors (e.g., cyclosporine, eltrombopag), strong CYP2C8 inducers (e.g., rifampin), monoamine oxidase inhibitors (MAOIs), and drugs or over-the-counter medications that can increase norepinephrine or serotonin [e.g., opioids, selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), tricyclics, tyramine].

Mayzent may also interact with QT prolonging drugs, calcium channel blockers, other drugs that may decrease heart rate, beta-blockers, fluconazole, rifampin, carbamazepine, modafinil, and efavirenz.

Common side effects of Zeposia include:

• upper respiratory infection,
• liver transaminase elevation,
• dizziness on standing (orthostatic hypotension),
• urinary tract infection (UTI),
• back pain,
• high blood pressure (hypertension), and
• upper abdominal pain

Tell your doctor all medications and supplements you use.

Common side effects of Mayzent include:

• headache,
• high blood pressure (hypertension),
• increased transaminase,
• falls,
• swelling of extremities,
• nausea,
• dizziness,
• diarrhea,
• slow heart rate, and
• pain in extremities

Zeposia (ozanimod) is a sphingosine 1- phosphate receptor modulator used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults.

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Zeposia may interact with:

• anti-neoplastic medications,
• immune-modulating drugs,
• immunosuppressive therapies,
• anti-arrhythmics,
• live attenuated vaccines,
• strong CYP2C8 inhibitors (e.g., gemfibrozil),
• BCRP inhibitors (e.g., cyclosporine, eltrombopag),
• strong CYP2C8 inducers (e.g., rifampin),
• monoamine oxidase inhibitors (MAOIs), and
• drugs or over-the-counter medications that can increase norepinephrine or serotonin [e.g., opioids, selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), tricyclics, tyramine]

Tell your doctor all medications and supplements you use.

Mayzent may interact with:

• "live" vaccines,
• cancer medications,
• immune-modulating drugs,
• immunosuppressive therapies,
• anti-arrhythmics,
• QT prolonging drugs,
• calcium channel blockers,
• other drugs that may decrease heart rate,
• beta-blockers,
• fluconazole,
• rifampin,
• carbamazepine,
• modafinil, or
• efavirenz.

The recommended maintenance dosage of Zeposia is 0.92 mg orally once daily.

Initiate Mayzent with a 5-day titration. The recommended maintenance dosage of Mayzent is 2 mg.